← All trials
NCT00292201
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2006
- Primary completion
- Jun 1, 2013
- Completion date
- Jun 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 10
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Queen's University, BelfastLead sponsor
- The Physicians' Services Incorporated FoundationCollaborator
- Queen's University, BelfastOverall official - principal investigator
- Queen's University, BelfastReponsible party - principal investigator
- Canadian Lung AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.